Unbuzzd Wellness Inc., licensee of Quantum BioPharma Ltd., will host an investor webinar on September 16, 2025, featuring company executives discussing clinical data and investment opportunities for its alcohol metabolism beverage. CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David will present during the event focused on the Reg D 506(c) investment opportunity.
The webinar will highlight unbuzzd(TM), a beverage clinically shown to restore mental clarity, reduce hangover symptoms, and accelerate alcohol metabolism. Company executives will detail strategies to accelerate direct-to-consumer, distributor, and retail sales of what represents a significant advancement in alcohol-related wellness solutions. This presentation holds importance for stakeholders of both companies as Unbuzzd Wellness seeks to expand market penetration.
Quantum BioPharma, which invented unbuzzd(TM) and spun out its over-the-counter version to Unbuzzd Wellness, retains substantial financial interest in the product's success. According to the licensing agreement, Quantum BioPharma maintains 20.11% ownership of Unbuzzd Wellness as of March 31, 2025, and receives royalty payments of 7% of sales until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company also retains full rights to develop similar products for pharmaceutical and medical applications.
While Unbuzzd Wellness focuses on commercializing the wellness beverage, Quantum BioPharma continues its core biopharmaceutical research through subsidiary Lucid Psycheceuticals Inc., developing Lucid-MS for multiple sclerosis treatment while maintaining strategic investments through FSD Strategic Investments Inc. Additional company information is available through its newsroom at https://ibn.fm/QNTM.
The development of scientifically validated alcohol metabolism products represents a growing segment within the wellness industry, addressing consumer demand for evidence-based solutions to alcohol-related concerns. This investor webinar provides insight into both the scientific validation and commercial potential of such innovations, highlighting the intersection of biotechnology and consumer health products.
